Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

Glaxosmithkline Phar

₹2241.8 -23.3 | 1%

Market Cap ₹37977 Cr.

Stock P/E 64.4

P/B 22.7

Current Price ₹2241.8

Book Value ₹ 98.7

Face Value 10

52W High ₹3088

Dividend Yield 1.43%

52W Low ₹ 1764.9

Glaxosmithkline Phar Research see more...

Overview Inc. Year: 1924Industry: Pharmaceuticals & Drugs

GlaxoSmithKline Pharmaceuticals Ltd is a pharmaceutical enterprise. The Company is engaged in the business of manufacturing, distributing, and trading in prescription drugs. It manufactures medicinal materials used in the manufacture of prescription drugs, inclusive of antibiotics, endocrine products, basic nutrients; opium derivatives; sulpha tablets; serums and plasmas; salicylic acid, its salts, and esters; glycosides and vegetable alkaloids, and chemically natural sugar. It gives various prescription drugs, vaccines, and consumer healthcare products. Its medication portfolio includes Adartrel, Bactroban, Combodart, and Duodart. Its vaccines portfolio consists of Ambirix, Cervarix, Fendrix, and Havrix. The Company's products consist of Betamethasone, Potassium Clavulanate with Amoxycillin and Pneumococcal Polysaccharide and Conjugate Vaccine. Its oral health merchandise include Sensodyne, parodontax and Polident. Its manufacturing unit is at Nashik.

Read More..

Glaxosmithkline Phar Share Price

New

| |

Volume
Price

Quarterly Price

Show Value Show %

Glaxosmithkline Phar Quarterly Results

#(Fig in Cr.) Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 745 917 802 787 762 957 805 930 815 1011
Other Income 28 22 23 28 36 28 28 30 36 35
Total Income 773 939 826 815 798 985 833 960 850 1045
Total Expenditure 596 660 574 618 618 668 587 673 584 689
Operating Profit 177 279 252 197 180 318 246 287 266 356
Interest 1 0 0 1 0 0 0 1 0 0
Depreciation 16 16 16 17 16 18 17 18 16 17
Exceptional Income / Expenses 0 0 -11 10 17 0 -163 2 0 5
Profit Before Tax 160 262 224 190 181 299 65 271 249 344
Provision for Tax 44 69 60 57 49 82 20 76 67 91
Profit After Tax 116 193 165 133 132 218 46 194 182 253
Adjustments 3 0 0 0 0 0 0 0 0 0
Profit After Adjustments 119 193 165 133 132 218 46 194 182 253
Adjusted Earnings Per Share 7 11.4 9.7 7.9 7.8 12.8 2.7 11.5 10.8 14.9

Glaxosmithkline Phar Profit & Loss

#(Fig in Cr.) Dec 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
Net Sales 2608 3363 2838 2908 2871 3128 3224 2926 3278 3252 3454 3561
Other Income 222 259 123 73 55 102 79 111 76 101 123 129
Total Income 2830 3622 2961 2982 2926 3230 3303 3036 3354 3352 3576 3688
Total Expenditure 2124 2788 2360 2489 2366 2527 2567 2327 2516 2447 2545 2533
Operating Profit 706 833 601 492 560 703 736 709 838 905 1031 1155
Interest 0 0 0 0 0 1 6 4 2 2 2 1
Depreciation 20 25 25 26 38 49 83 79 68 66 70 68
Exceptional Income / Expenses 26 -52 2 46 18 29 -341 -173 12 -1 -144 -156
Profit Before Tax 711 756 578 511 540 683 306 454 779 836 816 929
Provision for Tax 230 279 202 174 189 237 213 167 398 229 226 254
Profit After Tax 482 476 376 337 351 445 93 287 381 608 590 675
Adjustments 0 0 0 0 0 0 0 71 1314 3 0 0
Profit After Adjustments 482 476 376 337 351 445 93 358 1695 611 590 675
Adjusted Earnings Per Share 28.4 28.1 22.2 19.9 20.7 26.3 5.5 21.1 100 36 34.8 39.9

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 6% 6% 2% 3%
Operating Profit CAGR 14% 13% 8% 4%
PAT CAGR -3% 27% 6% 2%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 27% 9% 7% 4%
ROE Average 33% 26% 20% 20%
ROCE Average 46% 41% 33% 32%

Glaxosmithkline Phar Balance Sheet

#(Fig in Cr.) Dec 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Shareholder's Funds 1990 1829 2183 2007 2057 2140 1821 1478 2663 1741 1778
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 4 3 2 1 1 0 0 0 0 0 0
Other Non-Current Liabilities 155 194 3497 3699 2632 2860 180 179 159 125 108
Total Current Liabilities 889 1107 784 881 2949 2804 1022 1355 1698 1326 1525
Total Liabilities 3037 3133 6465 6588 7639 7804 3023 3012 4520 3193 3410
Fixed Assets 100 123 204 253 323 430 757 386 329 329 320
Other Non-Current Assets 313 423 3883 4500 3780 4015 491 423 483 370 292
Total Current Assets 2624 2587 2372 1833 3531 3356 1775 2023 3708 2494 2798
Total Assets 3037 3133 6465 6588 7639 7804 3023 3012 4520 3193 3410

Glaxosmithkline Phar Cash Flow

#(Fig in Cr.) Dec 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Opening Cash & Cash Equivalents 138 95 115 115 139 201 99 105 405 286 35
Cash Flow from Operating Activities 281 338 139 234 473 409 490 578 811 484 582
Cash Flow from Investing Activities 189 180 499 301 -104 -153 -57 418 -406 808 9
Cash Flow from Financing Activities -494 -497 -638 -511 -307 -358 -428 -696 -524 -1543 -561
Net Cash Inflow / Outflow -24 21 -0 24 62 -102 6 300 -119 -251 29
Closing Cash & Cash Equivalent 114 116 115 139 201 99 105 405 286 35 64

Glaxosmithkline Phar Ratios

# Dec 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Earnings Per Share (Rs) 28.43 28.12 22.2 19.88 20.7 26.29 5.5 21.14 100.04 36.05 34.83
CEPS(Rs) 29.61 29.62 23.68 21.44 22.95 29.16 10.38 21.6 26.5 39.75 38.94
DPS(Rs) 25 62.5 50 30 35 20 40 30 90 32 32
Book NAV/Share(Rs) 117.45 107.96 128.88 118.46 121.44 126.31 107.47 87.26 157.19 102.89 105.47
Core EBITDA Margin(%) 18.02 16.56 16.85 13.97 16.76 19.21 19.55 19.14 21.2 24.73 26.31
EBIT Margin(%) 26.54 21.8 20.4 17.05 17.89 21.84 9.28 14.64 21.73 25.78 23.68
Pre Tax Margin(%) 26.53 21.78 20.38 17.04 17.89 21.82 9.09 14.53 21.67 25.72 23.63
PAT Margin (%) 17.96 13.73 13.25 11.23 11.62 14.24 2.77 9.19 10.59 18.69 17.08
Cash Profit Margin (%) 18.7 14.46 14.13 12.11 12.88 15.79 5.23 11.71 12.49 20.71 19.1
ROA(%) 15.95 15.44 7.84 5.16 4.93 5.77 1.72 9.52 10.11 15.76 17.87
ROE(%) 24.1 24.95 18.75 16.08 17.26 21.22 4.71 17.42 18.39 27.58 33.43
ROCE(%) 35.54 39.53 28.81 24.39 26.56 32.54 15.76 27.74 37.72 38.06 46.49
Receivable days 14.45 10.35 14.59 18.09 19.21 15.6 11.96 18.42 21.37 22.32 21.9
Inventory Days 43.02 38.01 57.97 57.89 55.98 57.56 52.62 60.14 54.91 55.82 52.05
Payable days 92.83 81.61 87.58 79.21 115.38 122.52 106.45 119.53 140.69 143.05 144.03
PER(x) 52.63 60.5 85.59 68.79 50.36 49.44 226.34 68.13 16.62 36.73 55.8
Price/Book(x) 12.74 15.76 14.75 11.54 8.59 10.29 11.59 16.51 10.58 12.87 18.42
Dividend Yield(%) 1.67 1.84 1.32 1.1 1.68 1.54 3.21 2.08 5.41 2.42 1.65
EV/Net Sales(x) 8.94 8 10.85 7.66 5.7 6.67 6.21 7.94 7.84 6.54 9.22
EV/Core EBITDA(x) 33.04 32.29 51.21 45.26 29.21 29.65 27.18 32.8 30.67 23.51 30.89
Net Sales Growth(%) -3.13 28.96 -15.61 2.49 -1.27 8.94 3.08 -9.27 12.05 -0.8 6.21
EBIT Growth(%) -14.73 6.23 -23.45 -11.64 5.62 26.49 -54.32 46.6 70.71 7.32 -2.41
PAT Growth(%) -14.28 -1.09 -21.05 -10.46 4.13 26.99 -79.07 208.21 32.55 59.58 -2.91
EPS Growth(%) -14.28 -1.09 -21.05 -10.46 4.13 26.99 -79.07 284.26 373.19 -63.97 -3.39
Debt/Equity(x) 0 0 0 0 0 0 0 0 0 0 0
Current Ratio(x) 2.95 2.34 3.03 2.08 1.2 1.2 1.74 1.49 2.18 1.88 1.84
Quick Ratio(x) 2.56 2 2.36 1.6 1.03 1.02 1.26 1.09 1.87 1.53 1.49
Interest Cover(x) 2146.51 1612.26 1373.88 2045.74 2856.45 1232.59 49.26 129.56 391.29 462.54 454.77
Total Debt/Mcap(x) 0 0 0 0 0 0 0 0 0 0 0

Glaxosmithkline Phar Shareholding Pattern

# Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Promoter 75 75 75 75 75 75 75 75 75 75
FII 2.16 2.17 2.29 2.28 2.41 2.5 2.92 3.48 4.02 4.36
DII 10.65 10.54 10.28 10.3 10.25 10.02 8.65 7.9 7.5 7.33
Public 12.19 12.29 12.43 12.43 12.35 12.49 13.43 13.62 13.48 13.3
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 26%
  • Company is almost debt free.

Cons

  • Debtor days have increased from 143.05 to 144.03days.
  • Stock is trading at 22.7 times its book value.
  • The company has delivered a poor profit growth of 5% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Glaxosmithkline Phar News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....